author-photo

Herbert G. Sayer

University of Jena

139

Papers

3414

Citations

Citation Trend

Filter By

Papers (95) Sort By

Journal Conference Others

Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma.

2021 European Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)
Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.

2021 Annals of Hematology
Show All
- Source
- Cite
- Save
Citations (0)
Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy.

2021 Journal of Cancer Research and Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Melphalan 200 mg/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients.

2020 Bone Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (0)
Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies

2019 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials

2019 European Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (5)
Feasibility of HSCT vs consolidation therapy for AML patients aged 60-75 in CR1: A randomized phase III, multicentre EBMT study.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation

2018 Bone Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (4)
Response-Adapted Sequential Treatment with Azacitidine and Intensive Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML: Results of the RAS-Azic Trial of the East German Study Group (OSHO)

2017 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment

2017 Journal of Cancer Research and Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (13)